HK Stock Market Move | JACOBIO-B(01167) closing up over 4%. Pan-KRAS inhibitor approved for clinical trials in the United States.

JACOBIO-B (01167) rose over 4% at the close of trading, up 2.96% to HK$1.74 as of the time of writing, with a trading volume of HK$4.7074 million. On the news front, JACOBIO announced today that the Investigational New Drug (IND) application for the company's Pan-KRAS inhibitor JAB-23E73, developed independently, has been approved in the United States and will conduct Phase I/IIa clinical trials on late-stage solid tumors in the US. The IND application in China has been submitted and will conduct clinical trials in China simultaneously upon approval. It is reported that KRAS is widely present in various tumor mutations, with 23%-25% of cancer patients having KRAS mutations, and an estimated 2.7 million new cancer patients with KRAS-related mutations worldwide are expected to benefit from the Pan-KRAS inhibitor. Furthermore, as an oral KRAS inhibitor, preclinical data for JAB-23E73 has demonstrated favorable pharmacokinetic properties.